Related Experiment Video
Updated: Jun 11, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Real-world experience with cefiderocol in hematologic patients with malignancies
Ana Martinez-Urrea1, Laura Mezzogori2, Antonio Gallardo-Pizarro1
1Infectious Disease Department, Hospital Clinic of Barcelona-Institut d'Investigacions Biomèdiques Agust Pi i Sunyer (IDIBAPS), Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
Summary
Cefiderocol showed clinical response in hematologic patients with multidrug-resistant infections. However, emerging resistance necessitates further research to optimize its clinical use.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacology
Background:
- Limited real-world data exists on cefiderocol efficacy in immunocompromised patients.
- Hematological malignancy patients often face challenging infections due to multidrug-resistant organisms (MDR).
Purpose of the Study:
- To characterize the use and outcomes of cefiderocol in patients with hematological malignancies.
- To evaluate cefiderocol's effectiveness and safety in treating MDR infections in this vulnerable population.
Main Methods:
- Retrospective, multicenter study.
- Inclusion of consecutive hematological malignancy patients treated with cefiderocol across two tertiary hospitals in Spain and Italy.
- Data collection on patient demographics, prior antibiotic exposure, pathogen identification, and treatment outcomes.
Main Results:
- Twenty-eight patients received cefiderocol; 85.7% had prior broad-spectrum antibiotic exposure, and 57.1% were colonized with MDR organisms.
- Pseudomonas aeruginosa was the most frequent pathogen (46.4%). Cefiderocol resistance emerged in 30.0% of empirical Gram-negative infections and 42.9% of MDR Gram-negative bacterial cases.
- Overall 30-day mortality was 35.7%, with some cases of clinical cure but also new colonizations with resistant strains.
Conclusions:
- Cefiderocol demonstrated clinical response and no safety concerns in hematologic malignancy patients with MDR infections.
- Emerging cefiderocol resistance is a significant concern that requires further investigation to optimize its role in clinical practice.
- Future research should focus on strategies to mitigate resistance development and guide appropriate cefiderocol utilization.
